Vertex PharmaceuticalsWBO:VRTX +0.52%91 Days Payable is 109.78 as of Mar. 2026, which is 26% above its 10-year median of 87.07. GuruFocus rates WBO:VRTX with a GF Score™ of 91/100 and a GF Value™ of €440.30 (Fairly Valued). The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 53.84% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VRTX vs REGN, ALNY, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vertex Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (WBO:VRTX) has a Days Payable of 109.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vertex Pharmaceuticals and its competitors. This is 26% above median its historical median of 87.07. Over the past decade, Vertex Pharmaceuticals' Days Payable has ranged from 60.16 to 118.27. According to the industry distribution chart, Vertex Pharmaceuticals ranks #379 out of 704 companies in the Biotechnology industry, placing it in the top 53.8%.
Is Vertex Pharmaceuticals' Days Payable too high?
Vertex Pharmaceuticals' current Days Payable of 109.78 is 26% above median its 10-year median of 87.07. Over the past 10 years, this metric has ranged from a low of 60.16 to a high of 118.27. The Biotechnology industry median Days Payable is 113.56. Vertex Pharmaceuticals' value of 109.78 is 3.3% below this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #379 out of 704 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Days Payable compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #379 out of 704 companies for Days Payable. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. Vertex Pharmaceuticals' value of 109.78 is 3.3% below this benchmark. Historically, Vertex Pharmaceuticals' own Days Payable has ranged from 60.16 to 118.27 over the past decade. While the company's 10-year median is 87.07 vs. the industry median of 113.56, Vertex Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current Days Payable of 109.78 is 3.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current Days Payable is 109.78, which is 26% above median its own 10-year median of 87.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €440.30, compared to a current price of €435.40 — trading 1.1% below its estimated fair value. The current Days Payable is 109.78, which is 26% above median its 10-year median of 87.07 and 3.3% below the Biotechnology industry median of 113.56. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current Days Payable is 109.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of €435.40 is trading 1.1% below its estimated GF Value™ of €440.30.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for WBO:VRTX:
Days Payable: 109.78 (26% above median its 10-year median of 87.07)
GF Value™: €440.30 vs. price of €435.40 (1.1% below fair value)
Industry Position: 3.3% below the Biotechnology median (#379 of 704)
No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score
Get the complete analysis for WBO:VRTX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VRTX has been successfully added to your 
